[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Important Steps for Dealing with High Risk Multiple Myeloma with Dr. Guido Tricot, MD, PhD, University of Iowa

Important Steps for Dealing with High Risk Multiple Myeloma with Dr. Guido Tricot, MD, PhD, University of Iowa image

Important Steps for Dealing with High Risk Multiple Myeloma with Dr. Guido Tricot, MD, PhD, University of Iowa

Podcast
event Dec 05, 2015 / 11:00AM MST
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Dr. Guido Tricot, MD, PhD University of Iowa Interview Date: December 5, 2015 

Dr. Tricot joins Myeloma Crowd Radio from the ASH 2015 conference in Orlando to talk about high risk myeloma. While standard treatments have become much more effective, 15-20% of patients have high risk disease and are not gaining longer life, even with the newer combinations. He notes the difference between more mature myeloma cells, which can't propogate the disease vs. the myeloma stem cells, but notes that if there is a large tumor burden, the sheer amount can create disease increase. Because the quanitity of cells can cause growth, he suggests that patients move to immediate transplant so they are hit with aggressive treatment when they are still naive to the drugs. One of the most important things patients can do with high risk disease is to make sure that the treatments are given on time with short induction periods. Dr. Tricot shares experience from the Total Therapy studies that patients with 17p deletion benefit with proteasome inhibitors like bortezomib and notes that they should also be used as maintenance therapy where iMiDs may actually be detrimental as maintenance. He has hope for checkpoint inhibitors and is looking forward to incorporating the new monoclonal antibodies in addition to standard treatments. He clarifies the definition of high-risk in patients with del13. He is focusing on new treatments for the MAF translocations using a Notch 2 inhibitor and is working on identifying a marker using flow cytometry that identifies response to treatment. Once tested, it would identify patients who have responded and or not responded and would help determine the course of treatment.

Takeda-300x100 

Thanks to our episode sponsor Takeda Oncology

Schedule & Agenda

Event panelist Dr. Guido Tricot & Jenny Ahlstrom
11:00 AM
Discussion
Dr. Guido Tricot & Jenny Ahlstrom

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.